{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Pelitinib",
  "nciThesaurus": {
    "casRegistry": "257933-82-7",
    "chebiId": "CHEBI:38927",
    "chemicalFormula": "C24H23ClFN5O2",
    "definition": "A 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity.  Pelitinib irreversibly binds covalently to epidermal growth factor receptors (EGFR) ErbB-1, -2 and -4, thereby inhibiting receptor phosphorylation and signal transduction and resulting in apoptosis and suppression of proliferation in tumor cells that overexpress these receptors.",
    "fdaUniiCode": "X5DWL380Z6",
    "identifier": "C2713",
    "preferredName": "Pelitinib",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C129825",
      "C2167"
    ],
    "synonyms": [
      "(2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide",
      "EKB 569",
      "EKB-569",
      "PELITINIB",
      "Pelitinib",
      "WAY-EKB 569"
    ]
  }
}